Explore AstraZeneca PLC's latest 6-K report detailing a transaction by Non-Executive Director Karen Knudsen involving 9 ADSs. Key insights for September 2025 compliance.
Explore AstraZeneca PLC's June 2025 report detailing an insider transaction by CFO Aradhana Sarin, showcasing corporate governance through a charitable gift of shares.
AstraZeneca PLC's recent Form 6-K reveals Non-Executive Director Karen Knudsen's purchase of 1,400 ADSs, reflecting confidence in the company's future. Key insights on compliance and market sentiment.
Explore Centessa Pharmaceuticals PLC's latest 8-K report, revealing crucial stock details and financial data. Essential for investors and analysts in the biotech sector.
Foresight Autonomous Holdings Ltd. updates on ADS offering, increasing maximum price to $11.4M. Legal compliance and investor transparency highlighted in Form 6-K report.
SaverOne's February 2025 Form 6-K highlights a strategic adjustment in share ratios to meet Nasdaq requirements, ensuring compliance and transparency for investors.
This report details SaverOne's amendment to Form 6-K, correcting the ADS ratio to 1-for-13.33 effective Feb 21, 2025, impacting trading on Nasdaq and equity awards.
Discover SaverOne 2014 Ltd.'s amended Form 6-K/A, detailing a reverse stock split to comply with Nasdaq's $1.00 price rule. Effective February 21, 2025.
SaverOne 2014 Ltd. reports a reverse stock split to meet Nasdaq's $1 minimum bid requirement. Effective Feb 21, 2025, 1 ADS will equal 1,200 ordinary shares.
Explore TC BioPharm's recent Form 6-K filing detailing the ADS ratio change, trading impacts, and warrant adjustments, essential for investors and stakeholders.
Explore Evaxion Biotech A/S's latest Form 6-K report detailing capital increases, public offerings, and warrant grants, crucial for investors and stakeholders.
Jianzhi Education Technology Group's American depositary shares fall below $1.00, triggering Nasdaq compliance action. The report details their 180-day plan to regain compliance.